| Theme | Selection of New Drug for Calcium and Phosphate Disorder | |
|---|---|---|
| Title | Calcimimetics: discovery of promise as therapeutic agents | |
| Publish Date | 2003/01 | |
| Author | Michihito Wada | Pharmaceutical Development Laboratories, Kirin Brewery Co., Ltd. |
| Author | Nobuo Nagano | Pharmaceutical Development Laboratories, Kirin Brewery Co., Ltd. |
| [ Summary ] | Nemeth, E. F. and his colleagues (NPS Pharmaceuticals, Inc.) have identified small organic compounds named "calcimimetics" that can activate the calcium receptor on parathyroid cells and suppress parathyroid hormone (PTH) secretion. The calcimimetic KRN1493 has undergone clinical trials, and the results reveal that the compound is well tolerated and can lower circulating levels of PTH and calcium×phosphorus products in patients with secondary hyperparathyroidism. These preliminary findings indicate that the calcimimetic KRN1493 has potential as a therapeutic agent to treat hyperparathyroidism and related mineral disorders in patients with chronic renal insufficiency. | |